Page 14 - ITPS-5-2

8 INNOSC Theranostics and Pharmacological Sciences, 2022, Vol. 5, No. 2
8. Conclusions
Multiple, intricate mechanisms lead to the
emergence of NP. Animal models were used
to better define the therapy objectives and to
comprehend the pathophysiological mechanisms.
Given that agmatine has numerous targets that
are likewise implicated in NP and open up
novel therapeutic possibilities, there have been
numerous scientific studies on the impact of
agmatine on NP. Agmatine has a high safety profile
and has not been demonstrated to negatively affect
behavior, locomotion, or cardiovascular systems
in naive animals. According to experimental
investigations, agmatine has shown considerable
potential for the development of effective
treatment for this illness.
Acknowledgments
None.
Funding
None.
Conflict of interest
The authors declare no conflicts of interest.
Author contributions
Conceptualization: Mayur Kale
Visualization: Madhura Dixit, Manish Aglawe
Writing – original draft: Mrunali Dhokne
Writing – review &editing: Brijesh Taksande,
Milind Umekar
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data
Not applicable.
References
[1] Jensen, T.S.; Finnerup, N.B. Allodynia and Hyperalgesia in
Neuropathic Pain: Clinical Manifestations and Mechanisms.
Lancet Neurol., 2014, 13(9), 924–35.
[2] Costigan, M.; Scholz, J.; Woolf, C.J. Neuropathic Pain:
©2022 AccScience Publishing
Dhokne et al.
A Maladaptive Response of the Nervous System to Damage. Annu.
Rev. Neurosci., 2009, 32, 1–32.
[3] Smith, G.; Wiseman, J.; Harrison, S.; Elliott, P.; Birch, P. Pre
Treatment with MK-801, a non-Competitive NMDA Antagonist,
Prevents Development of Mechanical Hyperalgesia in a Rat
Model of Chronic Neuropathy, but not in a Model of Chronic
Inflammation. Neurosci. Lett., 1994, 165(1-2), 79–83.
[4] Mao, J.; Price, D.D.; Mayer, D.J.; Lu, J.; Hayes, R.L. Intrathecal
MK-801 and Local Nerve Anesthesia Synergistically Reduce
Nociceptive Behaviors in Rats with Experimental Peripheral
Mononeuropathy. Brain Res., 1992, 576(2), 254–62.
[5] Moncada, S.; Higgs, A. Mechanisms of Disease: The L-arginine-
[6] nitric Oxide Pathway. N. Engl. J. Med., 1993, 329(27), 2002–12.
Rodrigo, J.; Springall, D.R.; Uttenthal, O.; Bentura, M.L.;
Abadia-Molina, F.; Riveros-Moreno, V.; Martinez-Murillo, R.;
Polak, J.M.; Moncada, S. Localization of Nitric Oxide Synthase in
the Adult Rat Brain. Philos.Trans. R. Soc. Lond. B Biol. Sci., 1994,
345(1312), 175–221.
[7] Önal, A.; Delen, Y.; Ülker, S.; Soykan, N. Agmatine Attenuates
Neuropathic Pain in Rats: Possible Mediation of Nitric Oxide and
Noradrenergic Activity in the Brainstem and Cerebellum. Life Sci.,
2003, 73(4), 413–28.
[8] Rahangdale, S.; Fating, R.; Gajbhiye, M.; Kapse, M.; Inamdar, N.;
Kotagale, N.; Umekar, M.; Taksande, B. Involvement of Agmatine
in Antidepressant-like Effect of HMG-CoA Reductase Inhibitors in
Mice. Eur. J. Pharmacol., 2021, 892, 173739.
[9] Taksande, B.G.; Kotagale, N.R.; Tripathi, S.J.; Ugale, R.R.;
Chopde, C.T. Antidepressant Like Effect of Selective Serotonin
Reuptake Inhibitors Involve Modulation of Imidazoline Receptors
[10] by Agmatine. Neuropharmacol, 2009, 57(4), 415–24.
Courteix, C.; Privat, A.M.; Pélissier, T.; Hernandez, A.;
Eschalier, A.; Fialip, J. Agmatine Induces Antihyperalgesic
Effects in Diabetic Rats and a Superadditive Interaction with R
(–)-3-(2-Carboxypiperazine-4-yl)-Propyl-1-Phosphonic acid, a
N-Methyl-D-aspartate-receptor Antagonist. J. Pharmacol. Exp.
Ther., 2007, 322(3), 1237–45.
[11] Aglawe, M.M.; Taksande, B.G.; Kuldhariya, S.S.; Chopde, C.T.;
Umekar, M.J.; Kotagale, N.R. Participation of Central Imidazoline
Binding Sites in Antinociceptive Effect of Ethanol and Nicotine in
Rats. Fundam. Clin. Pharmacol., 2014, 28(3), 284–93.
[12] Kale, M.; Nimje, N.; Aglawe, M.M.; Umekar, M.; Taksande, B.;
Kotagale, N. Agmatine Modulates Anxiety and Depression-like
Behaviour in Diabetic Insulin-resistant Rats. Brain Res., 2020,
[13] 1747, 147045.
Otake, K.; Ruggiero, D.A.; Regunathan, S.; Wang, H.; Milner, T.A.;
Reis, D.J. Regional Localization of Agmatine in the Rat Brain: An
Immunocytochemical Study. Brain Res., 1998, 787(1), 1–14.
[14] Dixit, M.; Upadhya, M.; Taksande, B.; Raut, P.; Umekar, M.;
Kotagale, N. Neuroprotective Effect of Agmatine in Mouse Spinal
Cord Injury Model: Modulation by Imidazoline Receptors. J. Nat.
Sci. Biol. Med., 2018, 9(2), 115–20.
[15] Taksande, B.G.; Chopde, C.T.; Umekar, M.J.; Kotagale, N.R.
Agmatine Attenuates Hyperactivity and Weight Loss Associated
with Activity-based Anorexia in Female Rats. Pharmacol.
Biochem. Behav., 2015, 132, 136–41.
[16] Kotagale, N.R.; Shirbhate, S.H.; Shukla, P.; Ugale, R.R. Agmatine
Attenuates Neuropathic Pain in Sciatic Nerve Ligated Rats:
Modulation by Hippocampal Sigma Receptors. Eur. J. Pharmacol.,
2013, 714(1-3), 424–31.
[17] Kotagale, N.; Rahmatkar, S.; Chauragade, S.; Dixit, M.;
Umekar, M.; Chopde, C.; Taksande, B. Involvement of
Hippocampal Agmatine in β1-42 Amyloid Induced Memory
Impairment, Neuroinflammation and BDNF Signaling Disruption
in Mice. NeuroToxicology. 2020, 80, 1–11.
[18] Castelli, G.; Desai, K.M.; Cantone, R.E. Peripheral Neuropathy:
Evaluation and Differential Diagnosis. Am. Fam. Physician, 2020,
102(12), 732–9.
[19] Finnerup, N.B.; Kuner, R.; Jensen, T.S. Neuropathic Pain: From
Mechanisms to Treatment. Physiol Rev., 2021, 101(1), 259–301.